SY-5609
featured

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 465654

CAS#: 2417302-07-7

Description: SY-5609 is a highly potent (subnM CDK7 Kd) and selective, orally available inhibitor of CDK7 that entered the clinic in 2020. SY-5609 displays potent inhibition of CDK7 in cells and demonstrates strong efficacy in mouse xenograft models when dosed as low as 2 mg/kg.


Chemical Structure

img
SY-5609
CAS# 2417302-07-7

Theoretical Analysis

MedKoo Cat#: 465654
Name: SY-5609
CAS#: 2417302-07-7
Chemical Formula: C23H26F3N6OP
Exact Mass: 490.19
Molecular Weight: 490.471
Elemental Analysis: C, 56.32; H, 5.34; F, 11.62; N, 17.13; O, 3.26; P, 6.32

Price and Availability

Size Price Availability Quantity
5mg USD 850 2 Weeks
10mg USD 1550 2 Weeks
Bulk inquiry

Synonym: SY-5609; SY 5609; SY5609;

IUPAC/Chemical Name: (S)-7-(dimethylphosphoryl)-3-(2-((6,6-dimethylpiperidin-3-yl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)-1H-indole-6-carbonitrile

InChi Key: JDJOUBVVSQDIRC-AWEZNQCLSA-N

InChi Code: InChI=1S/C23H26F3N6OP/c1-22(2)8-7-14(10-30-22)31-21-29-12-17(23(24,25)26)18(32-21)16-11-28-19-15(16)6-5-13(9-27)20(19)34(3,4)33/h5-6,11-12,14,28,30H,7-8,10H2,1-4H3,(H,29,31,32)/t14-/m0/s1

SMILES Code: O=P(C)(C)C1=C(C#N)C=CC2=C1NC=C2C3=C(C(F)(F)F)C=NC(N[C@@H]4CNC(C)(C)CC4)=N3

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: To be determined

Shelf Life: >2 years if stored properly

Drug Formulation: To be determined

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 490.47 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Marineau JJ, Hamman KB, Hu S, Alnemy S, Mihalich J, Kabro A, Whitmore KM, Winter DK, Roy S, Ciblat S, Ke N, Savinainen A, Wilsily A, Malojcic G, Zahler R, Schmidt D, Bradley MJ, Waters NJ, Chuaqui C. Discovery of SY-5609: A Selective, Noncovalent Inhibitor of CDK7. J Med Chem. 2021 Nov 2. doi: 10.1021/acs.jmedchem.1c01171. Epub ahead of print. PMID: 34726887.

2: Panagiotou E, Gomatou G, Trontzas IP, Syrigos N, Kotteas E. Cyclin-dependent kinase (CDK) inhibitors in solid tumors: a review of clinical trials. Clin Transl Oncol. 2021 Aug 7. doi: 10.1007/s12094-021-02688-5. Epub ahead of print. PMID: 34363593.

3: Liang H, Du J, Elhassan RM, Hou X, Fang H. Recent progress in development of cyclin-dependent kinase 7 inhibitors for cancer therapy. Expert Opin Investig Drugs. 2021 Jan;30(1):61-76. doi: 10.1080/13543784.2021.1850693. Epub 2021 Jan 11. PMID: 33183110.

4: Sava GP, Fan H, Coombes RC, Buluwela L, Ali S. CDK7 inhibitors as anticancer drugs. Cancer Metastasis Rev. 2020 Sep;39(3):805-823. doi: 10.1007/s10555-020-09885-8. PMID: 32385714; PMCID: PMC7497306.